Skip to main content
Medical information Clinical review pending

Transplant Testing

HLA Single Antigen Bead Assay for Class I II IgG Antibodies DSASAB Class I II Test

The HLA Single Antigen Bead Assay for Class I II IgG Antibodies is a crucial test for assessing compatibility before organ transplantation, particularly kidney transplants. It identifies specific antibodies that could cause rejection.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Serum sample. Confirm specific volume requirements with the laboratory before booking.
Results
Approximately 10-12 days. Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test. However, please inform the laboratory of any medications you are currently taking.
Test priceKSh 100,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the HLA Single Antigen Bead Assay for Class I II IgG Antibodies DSASAB Class I II Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients awaiting organ transplantation (especially kidney)
  • ✓Individuals with a history of previous transplants
  • ✓Patients with autoimmune diseases
  • ✓Individuals experiencing unexplained organ dysfunction
  • ✓Patients with a family history of transplant rejection
  • ✓Monitoring patients post-transplant for antibody development
02

In plain language

What this test helps you understand

This test helps identify specific antibodies against HLA antigens, which is crucial for assessing the risk of transplant rejection and determining donor-recipient compatibility, particularly in kidney transplantation.
The HLA Single Antigen Bead Assay for Class I II IgG Antibodies is a diagnostic test used to evaluate the presence of specific antibodies that may impact organ transplantation. This test utilizes advanced Luminex X-Map technology to provide detailed information about antibodies against Class I and Class II HLA antigens. Understanding these antibodies is critical for assessing donor-recipient compatibility and predicting potential transplant rejection. This test is particularly important for individuals preparing for kidney transplantation. The results help healthcare providers, such as nephrologists, make informed decisions to improve the chances of a successful transplant. Discuss your results with your doctor to understand their implications for your specific situation.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test. However, please inform the laboratory of any medications you are currently taking.
SampleSerum sample. Confirm specific volume requirements with the laboratory before booking.
MethodologyLuminex X-Map technology is used to detect and quantify IgG antibodies against Class I and Class II HLA antigens.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects IgG antibodies against specific HLA antigens. It may not detect all types of antibodies or predict all forms of transplant rejection. Results should be interpreted alongside clinical information.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

HLA stands for Human Leukocyte Antigen. These are proteins found on the surface of cells that help the immune system distinguish between the body's own cells and foreign substances.
The test identifies antibodies that a patient may have against potential donor HLA antigens. These antibodies can attack the transplanted organ, leading to rejection. Identifying them helps select the most compatible donor.
The test measures the presence and levels of IgG antibodies against Class I and Class II HLA antigens in the patient's blood serum.
Your doctor will interpret the results based on the specific antibodies detected and their levels, considering your medical history and transplant plan. High levels of certain antibodies may indicate a higher risk of rejection.
No fasting is required for this test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp